logo
Share SHARE
FONT-SIZE Plus   Neg

4SC Receives Key Patent For Oncology Compound Resminostat In Japan

4SC AG (FSCGF.PK) Wednesday said it has been granted a key patent for its lead anti-cancer compound resminostat in Japan. The patent covers the composition of matter of resminostat, pharmaceutical compositions comprising resminostat and its therapeutic use in cancer and other therapeutic areas.

The company is engaged in the discovery and development of targeted small molecule drugs for autoimmune diseases and cancer. In April, 4SC granted an exclusive license to Yakult Honsha for the development and commercialization of resminostat in Japan. Hepatocellular carcinoma, the most common type of liver cancer, has a particularly high incidence in Japan.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Embark Veterinary Inc., a startup that makes dog DNA-testing kits for pet owners, vets and breeders, said it has raised $4.5 million in funding from investors and relocated its headquarters to Boston. The company intends to use the new funding to expand its canine genetic testing suite for pet owners, breeders, and veterinarians. Intel Corp. has completely shut down its wearables division about two weeks ago, CNBC reported, citing a person familiar with the matter. The company reportedly intends to focus on augmented reality. According to the CNBC report, Intel laid off about 80 percent of the team that made the Basis fitness watch in November 2016 and has now eliminated the division entirely. The Federal Trade Commission is investigating allegations that Amazon.com Inc. misled consumers about its pricing discounts, Reuters reported, citing a source close to the probe. The FTC probe is reportedly part of the agency's review of Amazon's proposed $13.4 billion deal to buy grocery chain Whole Foods Market Inc.
comments powered by Disqus
Follow RTT